Timely and comprehensive updating of treatment guidelines remains a challenge and necessity in medical oncology. Herein we discuss our assessment of how trial results with four off-patent drugs have been considered for integration into major guidelines in the absence of a commercial sponsor, in which we found reasons for concern.
This is a preview of subscription content, access via your institution
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Elliott, J. et al. Decision makers need constantly updated evidence synthesis. Nature 600, 383–385 (2021).
Ismaila, N., Salako, O., Mutiu, J. & Adebayo, O. Oncology guidelines usage in a low- and middle-income country. J. Glob. Oncol. 4, 1–6 (2018).
Edwards, P. et al. Identification of randomized controlled trials in systematic reviews: accuracy and reliability of screening records. Stat. Med. 21, 1635–1640 (2002).
Haddaway, N. R. et al. Eight problems with literature reviews and how to fix them. Nat. Ecol. Evol. 4, 1582–1589 (2020).
Harris, M. et al. Explicit bias toward high-income-country research: a randomized, blinded, crossover experiment of English clinicians. Health Aff. 36, 1997–2004 (2017).
Rauh, S. et al. Old drug, new clinical use, no man’s land for the indication: an awareness call from European experts. ESMO Open 5, e000615 (2020).
Burchert, A. et al. Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3-internal tandem duplication Mutation (SORMAIN). J. Clin. Oncol. 38, 2993–3002 (2020).
Xuan, L. et al. Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial. Lancet Oncol. 21, 1201–1212 (2020).
Kluetz, P. G. et al. FDA Oncology Center of Excellence project renewal: engaging the oncology community to update product labeling for older oncology drugs. Clin. Cancer Res. 27, 916–921 (2021).
Asker-Hagelberg, C. et al. Repurposing of medicines in the EU: launch of a pilot framework. Front. Med. 8, 817663 (2022).
The authors thank P. Pantziarka (Anticancer Fund) for discussions and assistance in preparing this article.
The authors declare no competing interests.
ASCO Guidelines Evidence Submission Form: https://www.surveymonkey.com/r/guidelineevidence
ASCO Guidelines Methodology Manual: https://www.asco.org/sites/new-www.asco.org/files/content-files/advocacy-and-policy/documents/2022-Guidelines-Methodology-Manual-with-links.pdf
ESMO eUpdate standard operating procedures: https://www.esmo.org/content/download/121792/2307979/1/ESMO-eUpdate-SOP.pdf
NCCN Submission Request History: https://www.nccn.org/guidelines/submissions-request-to-the-guidelines-panels/submission-request-history
Transparency of the NCCN Guidelines Development Process: https://www.nccn.org/guidelines/guidelines-process/transparency-process-and-recommendations
About this article
Cite this article
Bouche, G., Meheus, L. Ensuring completeness and timeliness of cancer treatment guidelines. Nat Rev Clin Oncol 19, 563–564 (2022). https://doi.org/10.1038/s41571-022-00646-w